Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study.

Markus Magerl Guido Schiffhorst Lena Fanter Gerrit Müller Christoph Hirche Fabian Berkemeier Emel Aygören

Published in: Allergy (2023)

This study contributes to current knowledge in the treatment of HAE by indicating a statistically significant reduction of HAE attacks under lanadelumab compared to pdC1-INH i.v.

Keyphrases

end stage renal disease
healthcare
newly diagnosed
chronic kidney disease
prognostic factors
case report
combination therapy
peritoneal dialysis
smoking cessation